In September 2025, the U.S. Food and Drug Administration (FDA) announced a regulatory change waiving the requirement for clinical efficacy studies for biosimilar monoclonal antibodies following advocacy from Professor Sarfaraz K. Niazi of the University of Illinois, Chicago (1). This major regulatory change represents a significant shift in biosimilar approval pathways and will beneficially impact the companies looking to bring biosimilar mAbs to the US market.
Biosimilars as a product class have consistently offered potential for lower-cost production and faster market access for drugs that successfully navigate the established truncated regulatory pathway. While global recognition of biosimilar potential exists, the uptake rates in a global sense have varied across all territories, with the European Medicines Agency (EMA) region demonstrating faster growth compared to the US market during initial years.
Regulatory agencies have published guidelines that establish expectations for companies seeking to market this class of product (2, 3, 4, 5). These guidelines demonstrate similar patterns in certain aspects, such as recognizing the need for detailed structural analysis according to ICH Q6B (6). However, they have slightly different approaches regarding clinical aspects of biosimilar product development.
Prior to this announcement, both the EMA and FDA required some degree of clinical data generation. However, several years ago the UK Medicines and Healthcare Regulatory Agency (MHRA), serving as the regulatory agency for the UK following Brexit, removed the automatic requirement for clinical efficacy trials for biosimilar applications in the UK market. This decision followed critical assessment of data from biosimilar applications in the EU.
The MHRA assessment covered several monoclonal antibody types and the fusion protein Etanercept. The agency determined that state-of-the-art analytics combined with comparative pharmacokinetic data, were sufficient in many cases to demonstrate biosimilarity in a product. With biosimilarity demonstrated in this way, clinical studies were not necessarily needed (5, 7).
Understand how regulatory expectations shape biosimilar testing - from primary sequence confirmation to advanced comparability analysis. This blog explains the structural and physico-chemical assays your biosimilar must undergo.
The FDA's adoption of critical consideration regarding clinical trial requirements for biosimilars, along with the subsequent reduction in biosimilar program costs for the US market, makes the biosimilars market in the US increasingly accessible to pharmaceutical companies that might not previously have considered entering this space.
This regulatory change benefits both the patients and the payers, who bear the cost of the drugs. The FDA's current focus on monoclonal antibodies may represent the beginning of a broader paradigm shift. The precedent established for mAbs raises questions about potential application to other biosimilars where biosimilarity has been demonstrated through similar analytical approaches.
This regulatory shift deserves recognition and stands as a significant achievement for Prof. Niazi. It reflects the success of his efforts to argue that clinical trials provide no meaningful data upon which a claim of biosimilarity will stand or fall. This decision by the FDA will inevitably direct attention towards other biosimilars in the US market beyond the mAb category.
Additional time may be required for FDA consideration of evidence regarding other classes of biosimilar product. but with their decision on mAbs it is likely just a matter of time before this removal of the need for clinical efficacy trials is adopted for other classes of biosimilar. This development carries global regulatory implications.
Currently, with both the MHRA and the FDA acknowledging that clinical trials are not appropriate markers of biosimilarity other agencies including the EMA which has announced a new streamlined approach in a draft guidance (8) will monitor the reaction and outcomes of this decision.
This shift away from clinical efficacy trials emphasizes that state-of-the-art analytics constitute a critical factor in the assessment of biosimilarity. Significant reliance on data derived from structural analyses requires partnering with companies and scientists possessing deep and extensive knowledge of biopharmaceutical products and expertise in application of state-of-the art analytical procedures and technologies. Such partnerships are essential to deliver meaningful and reliable data supporting biosimilar applications within this shifting regulatory landscape.
The FDA's decision to waive clinical efficacy studies for biosimilar monoclonal antibodies represents a significant regulatory evolution. As the regulatory landscape evolves, pharmaceutical companies and regulatory agencies worldwide will evaluate the outcomes of this regulatory shift. With the increased emphasis on state-of-the-art analytical characterization being the cornerstone of biosimilar approval, partnering with experienced analytical specialists becomes crucial for success.
BioPharmaSpec, with its deep expertise in biopharmaceutical analytics and cutting-edge analytical procedures, is uniquely positioned to support companies navigating this new regulatory environment. Our comprehensive understanding of biosimilar development, combined with advanced analytical technologies, ensures that clients can generate the meaningful and reliable data required to demonstrate biosimilarity in this evolving regulatory framework.
With clinical efficacy studies no longer required for biosimilar mAbs in the US, expert analytical support is more important than ever. Speak directly with a BioPharmaSpec scientist to ensure your characterization data meets the new FDA expectations.
